Front. Endocrinol. Frontiers in Endocrinology Front. Endocrinol. 1664-2392 Frontiers Media S.A. 10.3389/fendo.2025.1663787 Endocrinology Correction Correction: A decade of progress in type 2 diabetes and cardiovascular disease: advances in SGLT2 inhibitors and GLP-1 receptor agonists – a comprehensive review Aristizábal-Colorado David 1 2 Corredor-Rengifo David 1 2 Sierra-Castillo Santiago 3 López-Corredor Carolina 4 Vernaza-Trujillo David-Alexander 2 5 6 Weir-Restrepo Danilo 7 Izquierdo-Condoy Juan S. 8 * Ortiz-Prado Esteban 8 Rico-Fontalvo Jorge 9 10 Gómez-Mesa Juan-Esteban 11 12 Abreu-Lomba Alin 13 Rivera-Martínez Wilfredo-Antonio 2 14 1 Internal Medicine Department, Universidad Libre, Cali, Colombia 2 Grupo Interinstitucional de Medicina Interna (GIMI1), Universidad Libre, Cali, Colombia 3 Epidemiology Department, Universidad Centros de Estudios en Salud (CES), Medellín, Colombia 4 Medicine Program, Universidad Santiago de Cali, Cali, Colombia 5 Department of Public Health, Pontificia Universidad Javeriana, Cali, Colombia 6 Clinical Research Center, Clínica Imbanaco, Cali, Colombia 7 Internal Medicine Department, Universidad Centros de Estudios en Salud (CES), Medellin, Colombia 8 One Health Research Group, Universidad de las Américas, Quito, Ecuador 9 Department of Nephrology, Faculty of Medicine, Universidad Simón Bolívar, Barranquilla, Colombia 10 Latin American Society of Nephrology and Arterial Hypertension (SLANH), Ciudad de Panama, Panama 11 Cardiology Department, Fundación Valle del Lili, Cali, Colombia 12 Department of Health Sciences, Universidad Icesi, Cali, Colombia 13 Endocrinology Department, Clínica Imbanaco, Cali, Colombia 14 Endocrinology Department, Universidad de Antioquia, Medellín, Colombia

Approved by: Frontiers Editorial Office, Frontiers Media SA, Switzerland

*Correspondence: Juan S. Izquierdo-Condoy, juan1izquierdo11@gmail.com

20 08 2025 2025 16 1663787 10 07 2025 28 07 2025 Copyright © 2025 Aristizábal-Colorado, Corredor-Rengifo, Sierra-Castillo, López-Corredor, Vernaza-Trujillo, Weir-Restrepo, Izquierdo-Condoy, Ortiz-Prado, Rico-Fontalvo, Gómez-Mesa, Abreu-Lomba and Rivera-Martínez. 2025 Aristizábal-Colorado, Corredor-Rengifo, Sierra-Castillo, López-Corredor, Vernaza-Trujillo, Weir-Restrepo, Izquierdo-Condoy, Ortiz-Prado, Rico-Fontalvo, Gómez-Mesa, Abreu-Lomba and Rivera-Martínez

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

 A Correction on A decade of progress in type 2 diabetes and cardiovascular disease: advances in SGLT2 inhibitors and GLP-1 receptor agonists – a comprehensive review By Aristizábal-Colorado D, Corredor-Rengifo D, Sierra-Castillo S, López-Corredor C, Vernaza-Trujillo D-A, Weir-Restrepo D, Izquierdo-Condoy JS, Ortiz-Prado E, Rico-Fontalvo J, Gómez-Mesa J-E, Abreu-Lomba A and Rivera-Martínez W-A (2025) Front. Endocrinol. 16:1605746. doi: 10.3389/fendo.2025.1605746 cardiovascular outcomes SGLT2 inhibitors GLP-1 agonists combination therapy heart failure renal outcomes section-in-acceptance Cardiovascular Endocrinology

The affiliations “Department of Public Health, Pontificia Universidad Javeriana, Cali, Colombia” and “Clinical Research Center, Clı́nica Imbanaco, Cali, Colombia” were omitted for author David Alexander Vernaza Trujillo.

The original version of this article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.